Neurocrine Biosciences (NBIX) reported $814.5 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 42.3%. EPS of $1.94 for the same period compares to $0.08 a year ago.
The reported revenue represents a surprise of +9.8% over the Zacks Consensus Estimate of $741.78 million. With the consensus EPS estimate being $1.68, the EPS surprise was +15.31%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Neurocrine performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Product sales, net- INGREZZA: $656.9 million compared to the $595.65 million average estimate based on eight analysts. The reported number represents a change of +20.5% year over year. Revenues- Product sales, net: $811 million versus the eight-analyst average estimate of $720.97 million. The reported number represents a year-over-year change of +43.9%. Revenues- Product sales, net- CRENESSITY: $153.3 million compared to the $121.77 million average estimate based on eight analysts. Revenues- Collaboration revenue: $3.5 million versus the seven-analyst average estimate of $7.72 million. The reported number represents a year-over-year change of -60.7%. Revenues- Product sales, net- Other: $4.3 million versus $4.1 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.5% change.View all Key Company Metrics for Neurocrine here>>>
Shares of Neurocrine have returned +1.2% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).